UNLABELLED: This study evaluates the efficacy of low doses of pamidronate after renal transplantation to prevent bone loss in osteopenic patients. Results show that pamidronate is safe and significantly reduced spinal bone loss when administered immediately after renal transplantation. INTRODUCTION: The purpose of this work is to evaluate the efficacy of two intravenous infusions of pamidronate in the immediate post-transplant period in a renal transplant (RT) population. METHODS: In this 12-month, randomized, double-blind, multicenter trial, 39 kidney recipients with diagnosed osteopenia received two doses of 30 mg of disodium pamidronate (n = 24) orplacebo (n = 15), at surgery and 3 months post-RT. All patients received calcium and vitamin D. Bone density of the lumbar spine and total femur was measured by dual-energy X-ray absorptiometry (DXA) and X-rays were performed at RT, 6 and 12 months post-RT. Biochemical and hormonal determinations were performed before and after treatment. RESULTS:Pamidronate significantly reduced spinal bone loss, but no significant benefit was found for the incidence of fractures. Elevated baseline intact parathyroid hormone (iPTH) and bone remodeling markers returned to normal levels 3 months post-RT. However, normal procollagen type I N propeptide (PINP) concentrations were only maintained in the pamidronate group. After RT, a comparable graft function was observed in both groups according to creatinine values, 25-hydroxyvitamin-D (25-OH-D) levels were improved, and serum calcium levels normalized after a transient fall during the first 3 months. CONCLUSION: A low dose of pamidronate prevents bone loss in osteopenic patients when administered immediately after RT.
RCT Entities:
UNLABELLED: This study evaluates the efficacy of low doses of pamidronate after renal transplantation to prevent bone loss in osteopenicpatients. Results show that pamidronate is safe and significantly reduced spinal bone loss when administered immediately after renal transplantation. INTRODUCTION: The purpose of this work is to evaluate the efficacy of two intravenous infusions of pamidronate in the immediate post-transplant period in a renal transplant (RT) population. METHODS: In this 12-month, randomized, double-blind, multicenter trial, 39 kidney recipients with diagnosed osteopenia received two doses of 30 mg of disodium pamidronate (n = 24) or placebo (n = 15), at surgery and 3 months post-RT. All patients received calcium and vitamin D. Bone density of the lumbar spine and total femur was measured by dual-energy X-ray absorptiometry (DXA) and X-rays were performed at RT, 6 and 12 months post-RT. Biochemical and hormonal determinations were performed before and after treatment. RESULTS:Pamidronate significantly reduced spinal bone loss, but no significant benefit was found for the incidence of fractures. Elevated baseline intact parathyroid hormone (iPTH) and bone remodeling markers returned to normal levels 3 months post-RT. However, normal procollagen type I N propeptide (PINP) concentrations were only maintained in the pamidronate group. After RT, a comparable graft function was observed in both groups according to creatinine values, 25-hydroxyvitamin-D (25-OH-D) levels were improved, and serum calcium levels normalized after a transient fall during the first 3 months. CONCLUSION: A low dose of pamidronate prevents bone loss in osteopenicpatients when administered immediately after RT.
Authors: M Ninkovic; S J Skingle; P W Bearcroft; N Bishop; G J Alexander; J E Compston Journal: Eur J Gastroenterol Hepatol Date: 2000-08 Impact factor: 2.566
Authors: Wolfgang Grotz; Christian Nagel; Daria Poeschel; Markus Cybulla; Karl-Georg Petersen; Markus Uhl; Christoph Strey; Günter Kirste; Manfred Olschewski; Achim Reichelt; Lars Christian Rump Journal: J Am Soc Nephrol Date: 2001-07 Impact factor: 10.121
Authors: Maria Coco; Daniel Glicklich; Marie Claude Faugere; Larry Burris; Istvan Bognar; Peter Durkin; Vivian Tellis; Stuart Greenstein; Richard Schechner; Katherine Figueroa; Patricia McDonough; Guodong Wang; Hartmut Malluche Journal: J Am Soc Nephrol Date: 2003-10 Impact factor: 10.121
Authors: Christoph Schwarz; Christa Mitterbauer; Georg Heinze; Wolfgang Woloszczuk; Martin Haas; Rainer Oberbauer Journal: Kidney Int Date: 2004-01 Impact factor: 10.612
Authors: E Shane; M A Rodino; D J McMahon; V Addesso; R B Staron; M J Seibel; D Mancini; R E Michler; S H Lo Journal: J Heart Lung Transplant Date: 1998-11 Impact factor: 10.247
Authors: Martin Haas; Zdenka Leko-Mohr; Paul Roschger; Josef Kletzmayr; Christoph Schwarz; Christa Mitterbauer; Rudolf Steininger; Stefan Grampp; Klaus Klaushofer; Günter Delling; Rainer Oberbauer Journal: Kidney Int Date: 2003-03 Impact factor: 10.612
Authors: Antoine Bouquegneau; Syrazah Salam; Pierre Delanaye; Richard Eastell; Arif Khwaja Journal: Clin J Am Soc Nephrol Date: 2016-02-15 Impact factor: 8.237
Authors: Suetonia C Palmer; Edmund Ym Chung; David O McGregor; Friederike Bachmann; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2019-10-22